2026年4月15日 16:50 ET 发布 · 更新于 7 个月前 · 1 个来源
Portal CEO on Lilly Deal for Cancer Biotech CrossBridge
bloomberg
·
原始报道
INFERY
Portal Innovations CEO John Flavin provides a look into the 2026 biotech M&A pipeline and breaks down Eli Lilly’s purported acquisition of CrossBridge Bio for up to $300 million, bolstering its oncology segment. He talks with Katie Greifeld and Romaine Bostick on “The Close.” (Source: Bloomberg)
原文